The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting metabolic dysregulation of T cells in kidney cancer.
 
Katy Beckermann
Research Funding - Bristol-Myers Squibb
 
Kirsten Young
No Relationships to Disclose
 
Rachel Hongo
No Relationships to Disclose
 
Xiang Ye
No Relationships to Disclose
 
Diana Contreras
No Relationships to Disclose
 
Sierra Barone
No Relationships to Disclose
 
Caroline E. Roe
Employment - LabCorp (I); Pfizer (I)
Stock and Other Ownership Interests - LabCorp (I)
Honoraria - Fluidigm
Research Funding - Janssen; Pharmacyclics
 
Christof C. Smith
No Relationships to Disclose
 
Benjamin Garrett Vincent
Leadership - Select Immunogenomics
Research Funding - Merck; Merck
 
Jonathan M. Irish
Research Funding - Incyte (Inst); Janssen (Inst); Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Methods and Compositions for Risk Stratification, US Patent (US 7,393,656, US 7,939,278, US US 8,206,939, US 8,309,316, US 8,394,599)
Other Relationship - Cytobank
 
Wendy Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Publishing (I); Sitryx (I)
Honoraria - Merck (I); pfizer (I)
Consulting or Advisory Role - Caribou Biosciences (I); Sitryx (I)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (I); Calithera Biosciences (Inst); Incyte (I); Kadmon (I); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Tempus (I); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
Travel, Accommodations, Expenses - Caribou Publishing (I); Chinese Society for Immunology (I); Merck (I); Pfizer (I)
 
Jeffrey C. Rathmell
Leadership - Sitryx
Stock and Other Ownership Interests - Sitryx
Honoraria - merck
Consulting or Advisory Role - Merck
Research Funding - Calithera Biosciences; Incyte; Kadmon; Tempest Therapeutics
Travel, Accommodations, Expenses - Merck